{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-24-000150","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.111167+00:00","generated_at":"2026-05-30T01:59:30.045653+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeiGene Q3 revenue $1.0B (+28% YoY); BRUKINSA global revenue $690M; positive non-GAAP OP income","bullets":["Total revenue $1,001.6M (+28% YoY); product revenue $993.4M (+67% YoY).","GAAP operating loss narrowed to $120.3M from $134.0M; adjusted operating income $65.6M vs loss $16.3M.","BRUKINSA global revenue $690M; now #1 in new patient starts for frontline and R/R CLL in U.S.","Four NMEs entered clinic in Q3 (eight YTD); on track for 10+ in 2024; sonrotoclax & BGB-16673 in late-stage.","CEO cites strong momentum in hematology and solid tumor pipeline expansions globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-24-000150","json":"https://secwatch.observer/filing/0001651308-24-000150.json","markdown":"https://secwatch.observer/filing/0001651308-24-000150.md","text":"https://secwatch.observer/filing/0001651308-24-000150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/0001651308-24-000150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/bgne-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:59:30.045653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}